DeepMatter Group Plc (AIM: DMTR, “DeepMatter”, the “Group”), which focuses on digitalising chemistry, announces that its CEO, Mark Warne, has been invited to chair the Industrial Advisory Board (IAB) at
AstraZeneca’s Chronic kidney disease Drug Forxiga approved by European Commission
AstraZeneca’s Forxiga (dapagliflozin), has been approved by the European Commission (EC). It is now available for chronic kidney disease (CKD), in adults with or without type-2 diabetes (T2D), in the
DeepMatter Group PLC (DMTR.L) Collaboration with the University of Cambridge
DeepMatter collaborates with the University of Cambridge’s Innovation Centre in Digital Molecular Technologies
£400m Life Sciences hub in Stevenage To Be Built By GSK creating up to 5000 jobs
GSK, the pharmaceutical giant, plans to open a PS400m science hub at Stevenage. This could lead to up to 5,000 new jobs. Work is expected to start in 2022.
Green light for small cell lung cancer treatment given to AstraZeneca in China
Based on positive results in a phase III trial, Imfinzi demonstrated improvement over chemotherapy alone, the approval was granted
GLASGOW-based technology business DeepMatter has been chosen to work with English universities
On a project it is hoped could help speed the development of new vaccines and of anti-cancer drugs
DeepMatter Group PLC (DMTR.L) Collaborates with the Universities of Leeds and Sheffield
DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, has been selected as a partner for the University of Leeds following a £1.4M EPSRC investment they received to develop
Sareum Holdings PLC (SAR.L) Subscription to raise £900,000
Subscription to raise £900,000 to progress proprietary TYK2/JAK1 programmes through final stages of preclinical development
Sareum Holdings PLC (SAR.L) Research Update
Sareum Notes SRA737 Combination Data to be Presented at the AACR Annual Meeting
AstraZeneca to supply 31 million COVID-19 shots to EU in first quarter, a 60% cut
BRUSSELS (Reuters) – AstraZeneca Plc has informed European Union officials on Friday it would cut deliveries of its COVID-19 vaccine to the bloc by 60% to 31 million doses in
AstraZeneca expects to supply two million doses of COVID-19 vaccine every week in UK -The Times
(Reuters) – About two million doses of COVID-19 vaccine developed by Oxford University and AstraZeneca are set to be supplied every week by the middle of January in the United